Hi all, I’m back today talking about the approval of Avexis/Novartis’ gene therapy for spinal muscular atrophy, Zolgensma. I also talk about how I came to a conclusion about whether or not I should short Biogen.
Follow me on twitter @matthewlepoire
http://www.breakingbiotech.com
*this is not investment advice*
